Procept BioRobotics Corp’s filing revealed that its President, CEO Zadno Reza unloaded Company’s shares for reported $0.31 million on Mar 18 ’25. In the deal valued at $57.06 per share,5,475 shares were sold. As a result of this transaction, Zadno Reza now holds 173,070 shares worth roughly $10.26 million.
Then, Waters Kevin sold 733 shares, generating $41,825 in total proceeds. Upon selling the shares at $57.06, the EVP, CFO now owns 107,991 shares.
Before that, Shiblaq Hisham sold 247 shares. Procept BioRobotics Corp shares valued at $14,094 were divested by the EVP, Chief Comm. Officer at a price of $57.06 per share. As a result of the transaction, Shiblaq Hisham now holds 63,133 shares, worth roughly $3.74 million.
Morgan Stanley initiated its Procept BioRobotics Corp [PRCT] rating to an Overweight in a research note published on December 02, 2024; the price target was $105. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid November with a ‘”a Hold”‘ rating. Piper Sandler began covering PRCT with “an Overweight” recommendation on August 11, 2023. William Blair started covering the stock on May 31, 2023. It rated PRCT as “an Outperform”.
Price Performance Review of PRCT
On Monday, Procept BioRobotics Corp [NASDAQ:PRCT] saw its stock jump 2.10% to $59.29. Over the last five days, the stock has gained 8.91%. Procept BioRobotics Corp shares have fallen nearly -26.37% since the year began. Nevertheless, the stocks have fallen -14.31% over the past one year.
How much short interest is there in Procept BioRobotics Corp?
A steep rise in short interest was recorded in Procept BioRobotics Corp stocks on 2025-04-30, dropping by -0.52 million shares to a total of 5.81 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 6.34 million shares. There was a decline of -8.97%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 31, 2022 when BTIG Research began covering the stock and recommended ‘”a Neutral”‘ rating .
